{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:40:22Z","timestamp":1792194022172,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangzhou Science and Technology Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-55207-9","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T17:27:55Z","timestamp":1735579675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An antibody cocktail targeting two different CD73 epitopes enhances enzyme inhibition and tumor control"],"prefix":"10.1038","volume":"15","author":[{"given":"Jin-Gen","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6051-2251","authenticated-orcid":false,"given":"Xi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Chuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifeng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqing","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4427-7920","authenticated-orcid":false,"given":"Haidong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7376-1934","authenticated-orcid":false,"given":"Zeyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2062-7113","authenticated-orcid":false,"given":"Roberto","family":"Bellelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0270-9729","authenticated-orcid":false,"given":"Jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7837-653X","authenticated-orcid":false,"given":"Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Leng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6974-0486","authenticated-orcid":false,"given":"Yifan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7676-3337","authenticated-orcid":false,"given":"Li","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"55207_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl, L., Weng, C. H., Eghbali, S., Wolchok, J. D. & Merghoub, T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19, 37\u201350 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"55207_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nri.2016.4","volume":"16","author":"C Cekic","year":"2016","unstructured":"Cekic, C. & Linden, J. Purinergic regulation of the immune system. Nat. Rev. Immunol. 16, 177\u2013192 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"55207_CR3","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.str.2012.10.001","volume":"20","author":"K Knapp","year":"2012","unstructured":"Knapp, K. et al. Crystal structure of the human ecto-5\u2019-nucleotidase (CD73): insights into the regulation of purinergic signaling. Structure 20, 2161\u20132173 (2012).","journal-title":"Structure"},{"key":"55207_CR4","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41577-020-0376-4","volume":"20","author":"AK Moesta","year":"2020","unstructured":"Moesta, A. K., Li, X. Y. & Smyth, M. J. Targeting CD39 in cancer. Nat. Rev. Immunol. 20, 739\u2013755 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"55207_CR5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nrc.2017.110","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan, D., Young, A., Teng, M. W. L. & Smyth, M. J. Targeting immunosuppressive adenosine in cancer. Nat. Rev. Cancer 17, 765 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"55207_CR6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1158\/2159-8290.CD-14-0341","volume":"4","author":"A Young","year":"2014","unstructured":"Young, A., Mittal, D., Stagg, J. & Smyth, M. J. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 4, 879\u2013888 (2014).","journal-title":"Cancer Discov."},{"key":"55207_CR7","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1523\/JNEUROSCI.1118-18.2019","volume":"39","author":"A Yan","year":"2019","unstructured":"Yan, A. et al. CD73 promotes glioblastoma pathogenesis and enhances its chemoresistance via A(2B) adenosine receptor signaling. J. Neurosci. 39, 4387\u20134402 (2019).","journal-title":"J. Neurosci."},{"key":"55207_CR8","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1073\/pnas.0908801107","volume":"107","author":"J Stagg","year":"2010","unstructured":"Stagg, J. et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl Acad. Sci. USA 107, 1547\u20131552 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55207_CR9","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ijc.28456","volume":"134","author":"B Allard","year":"2014","unstructured":"Allard, B. et al. Anti-CD73 therapy impairs tumor angiogenesis. Int. J. Cancer 134, 1466\u20131473 (2014).","journal-title":"Int. J. Cancer"},{"key":"55207_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1348-8","volume":"15","author":"S Morello","year":"2017","unstructured":"Morello, S. et al. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. J. Transl. Med. 15, 244 (2017).","journal-title":"J. Transl. Med."},{"key":"55207_CR11","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-20-0076","volume":"19","author":"R Jin","year":"2020","unstructured":"Jin, R. et al. Dual mechanisms of novel CD73-targeted antibody and antibody-drug conjugate in inhibiting lung tumor growth and promoting antitumor immune-effector function. Mol. Cancer Ther. 19, 2340\u20132352 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"55207_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01733-x","volume":"22","author":"C Xia","year":"2023","unstructured":"Xia, C., Yin, S., To, K. K. W. & Fu, L. CD39\/CD73\/A2AR pathway and cancer immunotherapy. Mol. Cancer 22, 44 (2023).","journal-title":"Mol. Cancer"},{"key":"55207_CR13","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.drudis.2017.06.005","volume":"22","author":"L Antonioli","year":"2017","unstructured":"Antonioli, L. et al. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discov. Today 22, 1686\u20131696 (2017).","journal-title":"Drug Discov. Today"},{"key":"55207_CR14","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","volume":"72","author":"J Bendell","year":"2023","unstructured":"Bendell, J. et al. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol. Immunother. 72, 2443\u20132458 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"55207_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","volume":"19","author":"L Antonioli","year":"2013","unstructured":"Antonioli, L., Pacher, P., Vizi, E. S. & Hasko, G. CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 19, 355\u2013367 (2013).","journal-title":"Trends Mol. Med."},{"key":"55207_CR16","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1080\/19420862.2016.1143182","volume":"8","author":"JC Geoghegan","year":"2016","unstructured":"Geoghegan, J. C. et al. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action. MAbs 8, 454\u2013467 (2016).","journal-title":"MAbs"},{"key":"55207_CR17","doi-asserted-by":"publisher","first-page":"e004554","DOI":"10.1136\/jitc-2022-004554","volume":"10","author":"OL Gammelgaard","year":"2022","unstructured":"Gammelgaard, O. L. et al. Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity. J. Immunother. Cancer 10, e004554 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"55207_CR18","doi-asserted-by":"publisher","first-page":"18379","DOI":"10.1074\/jbc.RA120.012395","volume":"295","author":"JE Stefano","year":"2020","unstructured":"Stefano, J. E. et al. A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms. J. Biol. Chem. 295, 18379\u201318389 (2020).","journal-title":"J. Biol. Chem."},{"key":"55207_CR19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. 384, 238\u2013251 (2021).","journal-title":"N. Engl. J. Med."},{"key":"55207_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","volume":"9","author":"X Wang","year":"2018","unstructured":"Wang, X., Mathieu, M. & Brezski, R. J. IgG Fc engineering to modulate antibody effector functions. Protein Cell 9, 63\u201373 (2018).","journal-title":"Protein Cell"},{"key":"55207_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3390\/biomedicines10040825","volume":"10","author":"M Kellner","year":"2022","unstructured":"Kellner, M. et al. A novel anti-CD73 antibody that selectively inhibits membrane CD73 shows antitumor activity and induces tumor immune escape. Biomedicines 10, 825 (2022).","journal-title":"Biomedicines"},{"key":"55207_CR22","doi-asserted-by":"publisher","first-page":"e005802","DOI":"10.1136\/jitc-2022-005802","volume":"10","author":"RA Miller","year":"2022","unstructured":"Miller, R. A. et al. Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. J. Immunother. Cancer 10, e005802 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"55207_CR23","doi-asserted-by":"publisher","first-page":"609931","DOI":"10.3389\/fphar.2020.609931","volume":"11","author":"R Turiello","year":"2020","unstructured":"Turiello, R., Pinto, A. & Morello, S. CD73: a promising biomarker in cancer patients. Front. Pharm. 11, 609931 (2020).","journal-title":"Front. Pharm."},{"key":"55207_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26134-w","volume":"12","author":"E Schneider","year":"2021","unstructured":"Schneider, E. et al. CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression. Nat. Commun. 12, 5911 (2021).","journal-title":"Nat. Commun."},{"key":"55207_CR25","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.4049\/jimmunol.1301274","volume":"191","author":"MG Terp","year":"2013","unstructured":"Terp, M. G. et al. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J. Immunol. 191, 4165\u20134173 (2013).","journal-title":"J. Immunol."},{"key":"55207_CR26","doi-asserted-by":"publisher","first-page":"e1208875","DOI":"10.1080\/2162402X.2016.1208875","volume":"5","author":"CM Hay","year":"2016","unstructured":"Hay, C. M. et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology 5, e1208875 (2016).","journal-title":"Oncoimmunology"},{"key":"55207_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41592-021-01130-6","volume":"18","author":"G Weissenberger","year":"2021","unstructured":"Weissenberger, G., Henderikx, R. J. M. & Peters, P. J. Understanding the invisible hands of sample preparation for cryo-EM. Nat. Methods 18, 463\u2013471 (2021).","journal-title":"Nat. Methods"},{"key":"55207_CR28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674\u2013690 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"55207_CR29","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi, J. D., Surana, R., Valle, J. W. & Shroff, R. T. Pancreatic cancer. Lancet 395, 2008\u20132020 (2020).","journal-title":"Lancet"},{"key":"55207_CR30","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.pan.2021.03.018","volume":"21","author":"J Zhao","year":"2021","unstructured":"Zhao, J. et al. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Pancreatology 21, 942\u2013949 (2021).","journal-title":"Pancreatology"},{"key":"55207_CR31","doi-asserted-by":"publisher","first-page":"e142843","DOI":"10.1172\/jci.insight.142843","volume":"7","author":"E Tu","year":"2022","unstructured":"Tu, E. et al. Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC. JCI Insight 7, e142843 (2022).","journal-title":"JCI Insight"},{"key":"55207_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08123-8","volume":"10","author":"S Chen","year":"2019","unstructured":"Chen, S. et al. CD73 expression on effector T cells sustained by TGF-beta facilitates tumor resistance to anti-4-1BB\/CD137 therapy. Nat. Commun. 10, 150 (2019).","journal-title":"Nat. Commun."},{"key":"55207_CR33","doi-asserted-by":"publisher","first-page":"778978","DOI":"10.3389\/fimmu.2021.778978","volume":"12","author":"X Cui","year":"2021","unstructured":"Cui, X. et al. A novel bispecific antibody targeting PD-L1 and VEGF with combined anti-tumor activities. Front. Immunol. 12, 778978 (2021).","journal-title":"Front. Immunol."},{"key":"55207_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.canlet.2013.10.015","volume":"344","author":"Q Zhou","year":"2014","unstructured":"Zhou, Q., Facciponte, J., Jin, M., Shen, Q. & Lin, Q. Humanized NOD-SCID IL2rg-\/- mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. Cancer Lett. 344, 13\u201319 (2014).","journal-title":"Cancer Lett."},{"key":"55207_CR35","doi-asserted-by":"publisher","first-page":"1130358","DOI":"10.3389\/fimmu.2023.1130358","volume":"14","author":"RR Kowash","year":"2023","unstructured":"Kowash, R. R. & Akbay, E. A. Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer. Front. Immunol. 14, 1130358 (2023).","journal-title":"Front. Immunol."},{"key":"55207_CR36","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.stemcr.2018.02.009","volume":"10","author":"M Lupia","year":"2018","unstructured":"Lupia, M. et al. CD73 regulates stemness and epithelial-mesenchymal transition in ovarian cancer-initiating cells. Stem Cell Rep. 10, 1412\u20131425 (2018).","journal-title":"Stem Cell Rep."},{"key":"55207_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85379-z","volume":"11","author":"N Petruk","year":"2021","unstructured":"Petruk, N. et al. CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer. Sci. Rep. 11, 6035 (2021).","journal-title":"Sci. Rep."},{"key":"55207_CR38","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","volume":"27","author":"I Perrot","year":"2019","unstructured":"Perrot, I. et al. Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep. 27, 2411\u20132425 e2419 (2019).","journal-title":"Cell Rep."},{"key":"55207_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ijbiomac.2022.12.258","volume":"229","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y. et al. Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy. Int. J. Biol. Macromol. 229, 158\u2013167 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"55207_CR40","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1158\/1535-7163.MCT-21-0107","volume":"20","author":"M Wurm","year":"2021","unstructured":"Wurm, M. et al. A novel antagonistic CD73 antibody for inhibition of the immunosuppressive adenosine pathway. Mol. Cancer Ther. 20, 2250\u20132261 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"55207_CR41","doi-asserted-by":"crossref","unstructured":"Kleiveland, C. R. In: The impact of food bioactives on health: in vitro and ex vivo models (eds. K. Verhoeckx et al.) 161\u2013167 (2015).","DOI":"10.1007\/978-3-319-16104-4_15"},{"key":"55207_CR42","doi-asserted-by":"publisher","first-page":"e1320011","DOI":"10.1080\/2162402X.2017.1320011","volume":"6","author":"J Li","year":"2017","unstructured":"Li, J. et al. CD39\/CD73 upregulation on myeloid-derived suppressor cells via TGF-beta-mTOR-HIF-1 signaling in patients with non-small cell lung cancer. Oncoimmunology 6, e1320011 (2017).","journal-title":"Oncoimmunology"},{"key":"55207_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-1-61779-931-0_7","volume":"901","author":"C Zhang","year":"2012","unstructured":"Zhang, C. Hybridoma technology for the generation of monoclonal antibodies. Methods Mol. Biol. 901, 117\u2013135 (2012).","journal-title":"Methods Mol. Biol."},{"key":"55207_CR44","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s13361-012-0419-6","volume":"23","author":"BD Pascal","year":"2012","unstructured":"Pascal, B. D. et al. HDX workbench: software for the analysis of H\/D exchange MS data. J. Am. Soc. Mass Spectrom. 23, 1512\u20131521 (2012).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"55207_CR45","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.immuni.2021.09.008","volume":"54","author":"B Song","year":"2021","unstructured":"Song, B. et al. Ordered assembly of the cytosolic RNA-sensing MDA5-MAVS signaling complex via binding to unanchored K63-linked poly-ubiquitin chains. Immunity 54, 2218\u20132230 e2215 (2021).","journal-title":"Immunity"},{"key":"55207_CR46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"55207_CR47","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D. Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. Sect. D. Biol. Crystallogr."},{"key":"55207_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1107\/S0907444911001314","volume":"67","author":"GN Murshudov","year":"2011","unstructured":"Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. Sect. D. Biol. Crystallogr. 67, 355\u2013367 (2011).","journal-title":"Acta Crystallogr. Sect. D. Biol. Crystallogr."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55207-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55207-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55207-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T08:04:21Z","timestamp":1735632261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55207-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55207"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55207-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"26 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors except L.W., Y.H., Z.Y., J.C.Z., X.Wu, H.L., Z.C., M.W., X.Y., H. Shi, Y.X., R.B., S.D., J.He., J.Huang., and C.L.C. are employed by Huaota Biopharma. The author L.W., Y.H., Z.Y., J.C.Z., X.Wu, H.L., Z.C., M.W., X.Y., H. Shi, Y.X., R.B., S.D., J. He, J. Huang, and C.L.C. declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10872"}}